Plasma pTau217 levels and conversion to MCI in the Wisconsin Registry for Alzheimer’s Prevention and the Wisconsin ADRC - Poster presentation

Q: What was the study aim regarding plasma pTau217?

To examine the association between plasma pTau217 levels and conversion to MCI in a preclinical cohort.

Q: How were participants classified based on plasma pTau217?

Participants were categorized as plasma pTau217 negative (≤40 pg/ml) or positive (>40 pg/ml), and the positive group was further divided into moderately positive and strongly positive using specified cutoff ranges.

Sep 30, 2026

Upload by 4398046744996

Background: Evidence continues to support the accuracy and reliability of plasma pTau217 assays, prompting evaluation of their diagnostic and clinical utility. Objective: Assess the association between plasma pTau217 levels and conversion to mild cognitive impairment (MCI) in a preclinical cohort. Methods: 1943 participants with Quanterix HD-X plasma pTau217 data were classified as negative or positive, with positive subgroups defined by cutoffs. Incident MCI was defined using three stringency approaches, then conversion rates were estimated across groups.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages2

Reading Time5 min

AccessFree to download

Abstract

Background

Method

Result

Conclusion

DOI: 10. 1002/alz70856_105805 BIOMARKERS POSTER PRESENTATION BIOMARKERS (NON-NEUROIMAGING) Plasma pTau217 levels and conversion to MCI in the Wisconsin Registry for Alzheimer’s Prevention and the Wisconsin ADRC Julie E. Oomens1 Erin M. Jonaitis 1, 3 Rachael E. Wilson2 Nathaniel A. Chin 1 Ramiro Eduardo Rea Reyes2 Henrik Zetterberg2, 4, 5, 6, 7, 8 Sterling C Johnson9, 10 1Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 2Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA 3Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 4 Hong Kong Center for Neurodegenerative Diseases, Hong Kong, Science Park, China 5 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg, Molndal, Sweden 6 Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom 7 UK Dementia Research Institute, University College London, London, United Kingdom 8 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Västra Götaland län, Sweden 9Wisconsin Alzheimer’s Institute, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA 10Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA Correspondence Julie E. Oomens, Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. [Email:](Email: oomens@wisc.edu)[ oomens@wisc.edu](Email: oomens@wisc.edu) Abstract Background: As the evidence base supporting the accuracy and reliability of plasma pTau217 assays continues to grow, attention has shifted towards establishing their diagnostic and clinical utility. The aim of the current study was to examine the association between plasma pTau217 levels and conversion to MCI in a preclinical cohort. Method: We selected 1943 participants from the Wisconsin Registry for Alzheimer’s Prevention and the Wisconsin ADRC for whom Quanterix HD-X plasma pTau217 data was available. Participants were classified as being plasma pTau217 negative (≤ 40 pg/ml, n = 1402) or positive (> 40 pg/ml, n = 541), with the positive group also being subdivided into moderately positive (> 0.40 & ≤ 0. 63 pg/ml, n = 308) and strongly positive (> 0. 63 pg/ml, n = 233). Incident MCI was defined using varying levels of stringency and definitions included (1) conversion from CDR 0 to CDR 0.5 at two consecutive visits (n = 197, median 3 visits, mean FU 3.4 years; definition 1), (2) a clinical diagnosis of MCI from multidisciplinary consensus review (n = 1076, median 5 visits, mean FU 5.6 years; definition 2) and (3) performance below the 7th conditional centile on the PACC-3 for two consecutive visits (n = 948, median 3 visits, mean FU 6.6 years; definition 3). Result: The mean age of the included participants was 63 years (SD8. 1). 68% of participants were female, 35% of participants were APOE e4 carrier and 83% of participants were non-Hispanic white. Rates of conversion in the total cohort were < 1% per year (1.5% overall; average time to conversion 5.1 years) for definition 1, 1.1% per year(6.4%overall;average time to conversion7.3years)for definition2and < 1.0% per year (3. 9% overall; average time to conversion 5.7 years) for definition 3. Rates of conversion in the subset of pTau217 positive participants ranged from < 1.0% to 4.7% This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzhei

FAQs

What was the study aim regarding plasma pTau217?

To examine the association between plasma pTau217 levels and conversion to MCI in a preclinical cohort.

How were participants classified based on plasma pTau217?

Participants were categorized as plasma pTau217 negative (≤40 pg/ml) or positive (>40 pg/ml), and the positive group was further divided into moderately positive and strongly positive using specified cutoff ranges.

How was incident MCI defined in the analysis?

Incident MCI was defined using three different approaches, including conversion between CDR stages, clinical diagnosis from multidisciplinary consensus, and performance below a conditional centile on the PACC-3 across consecutive visits.

Sep 30, 2026

Upload by 4398046744996